Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Premature Labor (Tocolysis) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Premature Labor (Tocolysis) Overview | 8 | 1 |
| Pipeline Products for Premature Labor (Tocolysis) Comparative Analysis | 9 | 1 |
| Premature Labor (Tocolysis) Therapeutics under Development by Companies | 10 | 1 |
| Premature Labor (Tocolysis) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Premature Labor (Tocolysis) Pipeline Products Glance | 12 | 4 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Premature Labor (Tocolysis) Products under Development by Companies | 16 | 1 |
| Premature Labor (Tocolysis) Products under Investigation by Universities/Institutes | 17 | 1 |
| Premature Labor (Tocolysis) Companies Involved in Therapeutics Development | 18 | 6 |
| AMAG Pharmaceuticals, Inc. | 18 | 1 |
| GlaxoSmithKline Plc | 19 | 1 |
| Juniper Pharmaceuticals, Inc. | 20 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 21 | 1 |
| Lipocine Inc. | 22 | 1 |
| ObsEva SA | 23 | 1 |
| Premature Labor (Tocolysis) Therapeutics Assessment | 24 | 8 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 1 |
| Drug Profiles | 32 | 14 |
| bedoradrine sulfate Drug Profile | 32 | 3 |
| hydroxyprogesterone caproate Drug Profile | 35 | 1 |
| hydroxyprogesterone caproate Drug Profile | 36 | 2 |
| OBE-001 Drug Profile | 38 | 2 |
| OBE-022 Drug Profile | 40 | 1 |
| progesterone Drug Profile | 41 | 1 |
| retosiban Drug Profile | 42 | 1 |
| Small Molecule for Acute Inflammation and Premature Labor Drug Profile | 43 | 1 |
| Small Molecule to Agonize Progesterone Receptor for Preterm Birth Drug Profile | 44 | 1 |
| Small Molecules for Premature Labor Drug Profile | 45 | 1 |
| Premature Labor (Tocolysis) Dormant Projects | 46 | 1 |
| Premature Labor (Tocolysis) Discontinued Products | 47 | 1 |
| Premature Labor (Tocolysis) Product Development Milestones | 48 | 11 |
| Featured News &Press Releases | 48 | 1 |
| Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor | 48 | 1 |
| Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) | 48 | 1 |
| Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) | 49 | 1 |
| Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women | 50 | 1 |
| Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301 | 50 | 1 |
| Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena | 51 | 1 |
| Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection) | 51 | 1 |
| Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor | 52 | 1 |
| Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways | 52 | 1 |
| Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women | 53 | 1 |
| May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena | 54 | 1 |
| May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth | 54 | 1 |
| Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour | 55 | 1 |
| Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour | 56 | 1 |
| Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena | 56 | 3 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |